 |
|
|
Paul Utz
Email:
Phone:(650) 724-5421 Profile: http://med.stanford.edu/profiles/Paul_Utz/
Alternate Contact: Academic Appointments
Appointment
Organization
Associate Professor
Member
|
NIH Biosketch PDFHonors & Awards
Title
Organization
Date(s)
Immunology Graduate Program Teaching and Mentoring Award
Stanford University
2002
Divisional Teaching Award
Stanford University
2002
Proteomics Award Nominee
FOCIS
2000
Baxter Fellowship
Donald and Delia Baxter
2000
Stanford Clinical Medicine Award
Stanford University
1991
18 honors and awards: view full list
Administrative Appointments
Title
Organization
Start Year
End Year
Consultant
MedImmune
2004
2004
Consultant
Avanir, Inc.
2006
-
Consultant
Biogen/IDEC
2005
-
Consultant
Centocor/
Johnson and Johnson
2005
-
Scientific Advisory Board
XDX, Inc.
2005
2005
12 appointments: view full list
Professional Education
Degree
Awarding Institution
Field of Study
Year of Graduation
M.D.
Stanford University
Medicine
1991
B.S.
King's College
Biology
1986
Postdoctoral Advisees
Imelda Balboni,
Andrzej Chruscinski,
Alvina Chu,
Chih Liu
Web Site Links
Research/Lab website:
Utz Lab at Stanford
Research Interests
We are part of the Department of Medicine, Division of Immunology at Stanford University School of Medicine. Our lab is located in the brand new CCSR building, room 2215. We are interested in autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, myositis, primary biliary chirosis (PBC), Sjogren's disease, insulin dependent diabetes (type I diabetes or IDDM), multiple sclerosis (MS) and mixed connective tissue disease (MCTD). The Utz lab is comprised of approximately 12 scientists, including Postdoctoral Fellows, Research Assistants, Undergraduate Students and Graduate Students. The focus of our research centers on serum autoantibodies produced in a variety of autoimmune diseases. In addition to trying to better understand the pathogenic mechanisms involved in autoimmunity, we are interested in developing bench-to-bedside technologies, including diagnostics and therapeutics, for human autoimmune diseases.
The four major goals of our studies are:
(1) To understand the mechanisms by which highly-conserved, diverse molecules and complexes such as histones and splicing particles are targeted by T and B lymphocytes and to determine how an immune response directed against ubiquitous antigens leads to organ-specific autoimmune disease.
(2) To use autoimmune sera as molecular probes to study basic cellular processes, particularly apoptosis signaling pathways, alternative RNA splicing, and endoplasmic reticulum protein transport.
(3) To invent and validate novel technologies for high-throughput, multiplex proteomics signaling molecules and studies. We are currently focusing on proteomics analysis of proteins secreted by immune cells, including cytokines and autoantibodies.
(4) To take advantage of the information provided by autoantibody profiling methods to develop antigen-specific tolerizing therapies for common autoimmune diseases. We collaborate closely with the Stanford laboratory of Dr. Larry Steinman, the principle discoverer of DNA tolerizing technology. Our long-term goal is to develop patient-specific, individualized therapeutics.
The four major goals of our studies are:
(1) To understand the mechanisms by which highly-conserved, diverse molecules and complexes such as histones and splicing particles are targeted by T and B lymphocytes and to determine how an immune response directed against ubiquitous antigens leads to organ-specific autoimmune disease.
(2) To use autoimmune sera as molecular probes to study basic cellular processes, particularly apoptosis signaling pathways, alternative RNA splicing, and endoplasmic reticulum protein transport.
(3) To invent and validate novel technologies for high-throughput, multiplex proteomics signaling molecules and studies. We are currently focusing on proteomics analysis of proteins secreted by immune cells, including cytokines and autoantibodies.
(4) To take advantage of the information provided by autoantibody profiling methods to develop antigen-specific tolerizing therapies for common autoimmune diseases. We collaborate closely with the Stanford laboratory of Dr. Larry Steinman, the principle discoverer of DNA tolerizing technology. Our long-term goal is to develop patient-specific, individualized therapeutics.
Community and International Work
Publications
- Thibault DL, Chu AD, Graham KL, Balboni I, Lee LY, Kohlmoos C, Landrigan A, Higgins JP, Tibshirani R, Utz PJ "IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice." J Clin Invest 2008; More »
- Sharp V, Utz PJ "Technology Insight: can autoantibody profiling improve clinical practice?" Nat Clin Pract Rheumatol 2007; 3: 2: 96-103 More »
- Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ "Notch signals positively regulate activity of the mTOR pathway in T cell acute lymphoblastic leukemia." Blood 2007; More »
- Pennathur S, Baldessari F, Santiago JG, Kattah MG, Steinman JB, Utz PJ "Free-Solution Oligonucleotide Separation in Nanoscale Channels." Anal Chem 2007; More »
- Drouvalakis KA, Bangsaruntip S, Hueber W, Kozar LG, Utz PJ, Dai H "Peptide-coated nanotube-based biosensor for the detection of disease-specific autoantibodies in human serum." Biosens Bioelectron 2007; More »
46 publications: view full list
